Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials

SIMPLE SUMMARY: On the basis of the efficacy and tolerable safety profiles of immune checkpoints inhibitors (ICIs) in second-line metastatic urothelial carcinoma (mUC) patients, some emerging clinical trials focus on the first-line treatment. Thus, we conducted a network meta-analysis (NMA) to asses...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hsiao-Ling, Chan, Vinson Wai-Shun, Tu, Yu-Kang, Chan, Erica On-Ting, Chang, Hsiu-Mei, Juan, Yung-Shun, Teoh, Jeremy Yuen-Chun, Lee, Hsiang Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005008/
https://www.ncbi.nlm.nih.gov/pubmed/33807108
http://dx.doi.org/10.3390/cancers13061484

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005008/
https://www.ncbi.nlm.nih.gov/pubmed/33807108
http://dx.doi.org/10.3390/cancers13061484

Ejemplares similares